Otsuka establishes new European division in the UK
Otsuka Europe Development and Commercialisation (OEDC) in Uxbridge, Middlesex, will be the European research and development headquarters
Otsuka Pharmaceutical Co has formed a new UK-based European division dedicated to the development of pharmaceuticals.
The firm said Otsuka Europe Development and Commercialisation (OEDC) in Uxbridge, Middlesex, will be its European research and development headquarters and will work alongside Otsuka Pharmaceutical Europe (OPEL) to ensure successful the ‘successful development and commercialisation’ of products.
OEDC and OPEL are separate entities based at the same location. The firm said the ultimate aim is to build one fully integrated European company that will be able to respond effectively to an ‘increasingly rigorous regulatory environment’.
Dean Haubrich, President and CEO of OEDC, said: ‘We believe that Otsuka has a great deal to contribute to the health and well-being of people in Europe and we look forward to reinforcing our strong, positive presence.’
Otsuka Pharmaceutical has European operations in France, Germany, Italy, the Nordic region, Spain and the UK and employs more than 40,000 people worldwide.
